BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 23, 2024
Home
»
Newsletters
» BioWorld
BioWorld
March 5, 2009
View Archived Issues
Vertex Acquires ViroChem in $377M Cash-Stock Deal
Vertex Pharmaceuticals Inc. is buying Canadian drugmaker ViroChem Pharma Inc., a firm specializing in hepatitis C virus (HCV) and HIV drug development, for about $377 million in a cash-and-stock deal. (BioWorld Today)
Read More
Issues Facing Biotech, Pharma Converge to Boost M&A Activity
Read More
New Microbicide Shows Promise, Though Occult Infection Puzzling
Read More
Regulus' Coffer Gets Healthy with $20M from Benefactors
Read More
Pharmexa Acquires Affitech, Creating New Antibody Firm
Read More
Other News To Note
Read More
Clinic Roundup
Read More